style
highlight-section, no-side-margin
Mobile
An older woman and a younger woman standing outdoors, smiling and hugging each other closely.
Desktop
An older woman and a younger woman standing outdoors, smiling and hugging each other closely.

Discover Kisunla® ||| mb-0 py-3

section-id
hero-image

Kisunla is indicated for the treatment of adults with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease, who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers, and who have confirmed amyloid pathology.

Resources for healthcare professionals and patients coming soon

Access the Product Monograph
Sign up for product updates
style
gray bkg, py-4
section-id
Healthcare-resources

Please consult the Product Monograph at http://pi.lilly.com/ca/kisunla-ca-pm.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling at 1-888-545-5972.

Reference: ||| caption mb-0

Kisunla® Product Monograph. Eli Lilly Canada Inc. April 30, 2026. ||| caption